版本:
中国

BRIEF-Psivida's Durasert successfully achieves primary efficacy endpoint in second phase 3 study

June 13 Psivida Corp

* Psivida's Durasert three-year treatment for posterior segment uveitis successfully achieves primary efficacy endpoint in second phase 3 study

* Second phase 3 trial of Durasert three-year treatment for posterior segment uveitis achieved trial's primary endpoint

* Durasert three-year insert demonstrated a significant reduction in recurrence of posterior segment uveitis through six months

* Remain on track to also file a new drug application (NDA) with FDA in calendar Q4 of 2017

* Continue to expect submission of European Market Authorization Application (MAA) by end of June for treatment for posterior segment uveitis Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐